A Biocatalytic Continuous Flow Synthesis of (S)-Ketamine: Proof-of-Concept for Sustainable Pharmaceutical Manufacturing

This comprehensive feasibility study presents a transformative approach to pharmaceutical manufacturing through a novel biocatalytic continuous flow synthesis of (S)-ketamine. The work demonstrates how green chemistry principles can be practically implemented at industrial scale while maintaining economic viability. Key Innovations: Four-module continuous flow platform integrating palladium catalysis, biocatalytic dynamic kinetic resolution, green methylation chemistry, and membrane-based purification Projected 94% reduction in process mass intensity (PMI) from industry baseline of 280 to 16.1 kg/kg Elimination of all carcinogenic solvents and reagents 88% reduction in carbon footprint through validated lifecycle assessment Novel dual ω-transaminase system achieving >99% enantiomeric excess without chiral resolution waste Broader Impact: The study includes detailed policy recommendations for accelerating green pharmaceutical manufacturing adoption, specific implementation pathways for industry and academia, and critical research priorities with quantified investment needs. The technology platform is applicable to >50 commercial APIs, with detailed examples for bupropion, methadone, and atomoxetine demonstrating 85-90% waste reduction potential. Economic Viability: Financial modeling shows $21.3M capital investment with 2.6-year payback period, including enzyme development costs. Operating cost reductions of 52% are projected despite enzyme premiums. This work establishes a validated roadmap for sustainable pharmaceutical manufacturing and provides a replicable framework for biocatalytic process intensification across multiple API classes, supporting global initiatives for environmentally responsible drug production while enhancing accessibility through reduced manufacturing costs.